Compare CarMax, Inc (KMX) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Zoetis Inc — how do they compare? CarMax, Inc trades at $57.6 (market cap $7.93B), while Zoetis Inc trades at $75.13 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 4× CarMax, Inc's market cap, and Zoetis Inc pays a 2.78% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals.
| KMX | ZTS | |
|---|---|---|
Market Cap | $7.93B | $31.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $63.53 | $156.76 |
52-Week Low | $30.88 | $71.91 |
Enterprise Value | $26.44B | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $55.89, down 2.51% on the day, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company reported mixed earnings, with a Q2 2025 miss but subsequent beats in Q3 2025 and Q1 2026. Revenue has trended down from $31.9B in 2022 to $26.35B in 2025, though net income margin improved slightly to 1.89%. Recent news highlights a strategic turnaround under new CEO Keith Barr, with insider buying and positive analyst updates despite an ongoing legal investigation.
The outlook for KMX hinges on successful execution of its four-pillar strategy to boost volume and efficiency, offering potential upside if targets are met. However, high debt levels, margin pressure, and legal scrutiny pose significant risks. Analyst consensus is cautious with a hold-heavy rating and a price target of $48.91 below the current price, indicating skepticism about near-term growth.
Zoetis (ZTS) trades at $76.05, down 0.67% on the day, with a neutral technical signal and bearish moving averages. The company maintains strong fundamentals with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple securities class action lawsuits filed against the company, creating near-term uncertainty despite the launch of new product Lenivia in Canada and EU markets.
The stock presents a mixed outlook with attractive valuation metrics (P/E 12.55) and analyst consensus price target of $101.43 suggesting 33% upside potential. However, legal challenges and the recent earnings miss pose significant near-term risks. Institutional sentiment remains divided with 47% buy ratings versus 53% hold ratings, indicating cautious optimism amid legal headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
